Impact of atrial fibrillation on NT-proBNP levels in a 75-year-old population

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 69, Issue 5, 2009, Pages 579-584

  Ulimoen, Sara Reinvik ^a   Enger, Steve ^a   Tveit, Arnljot ^a  

^a VESTRE VIKEN HOSPITAL TRUST   (Norway)

Author keywords

Aged; Atrial fibrillation; NT proBNP; Population; Prevalence

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SINUS RHYTHM;

AGED; ATRIAL FIBRILLATION; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; NORWAY; PEPTIDE FRAGMENTS;

EID: 70249125406     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510902853305     Document Type: Article

References (32)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fi brillation in adults: national implications for rhythm management and stroke prevention. The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Am Med Assoc. 2001;285:2370-2375
2. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van HG, Stricker BH, Stijnen T, Lip GY, Witteman JC. Prevalence, incidence and lifetime risk of atrial fi brillation: the Rotterdam study. Eur Heart J. 2006;27:949-953
3. Tveit A, Abdelnoor M, Enger S, Smith P. Atrial fi brillation and antithrombotic therapy in a 75-year-old population. Cardiology. 2008;109:258-262
4. Hall C. NT-ProBNP: the mechanism behind the marker. J Card Fail. 2005;11(5 Suppl):S81-3.
5. Knudsen CW, Omland T, Clopton P, Westheim A, Wu AH, Duc P, McCord J, Nowak RM, Hollander JE, Storrow AB, Abraham WT, McCullough PA, Maisel A. Impact of atrial fi brillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the breathing not properly multinational study. J Am Coll Cardiol. 2005;46:838-844 (Pubitemid 41224808)
6. Shin DI, Jaekel K, Schley P, Sause A, Muller M, Fueth R, Scheffold T, Guelker H, Horlitz M. Plasma levels of NT-pro-BNP in patients with atrial fi brillation before and after electrical cardioversion. Z Kardiol. 2005;94:795-800.
7. Silvet H, Young-Xu Y, Walleigh D, Ravid S. Brain natriuretic peptide is elevated in outpatients with atrial fi brillation. Am J Cardiol. 2003;92:1124-1127
8. Inoue S, Murakami Y, Sano K, Katoh H, Shimada T. Atrium as a source of brain natriuretic polypeptide in patients with atrial fi brillation. J Card Fail. 2000;6:92-96
9. Asselbergs FW, van den Berg MP, Bakker SJ, Signorovitch JE, Hillege HL, van Gilst WH, van Veldhuisen. N-terminal pro B-type natriuretic peptide levels predict newly detected atrial fi brillation in a population-based cohort. Neth Heart J. 2008;16:73-78
10. Hou JL, Gao K, Li M, Ma JY, Shi YK, Wang Y, Zhao YF. Increased N-terminal pro-brain natriuretic peptide level predicts atrial fi brillation after surgery for esophageal carcinoma. World J Gastroenterol. 2008;14:2582-2585
11. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Salvatici M, Veronesi G, Veglia F, Fiorentini C, Spaggiari L, Cipolla CM. Increased perio-perative N-terminal pro-B-type natriuretic peptide levels predict atrial fi brillation after thoracic surgery for lung cancer. Circulation. 2007;115:1339-1344
12. Watanabe D, Shizuka K, Koyama S, Iwamoto T. Plasma brain natriuretic peptide levels indicating thromboembolism in very elderly patients with non-valvular atrial fi brillation. Circ J. 2007;71:1446-1451
13. Shimizu H, Murakami Y, Inoue S, Ohta Y, Nakamura K, Katoh H, Sakne T, Takahashi N, Ohata S, Sugamori T, Ishibashi Y, Shimada T. High plasma brain natriuretic-polypeptide level as a marker of risk for thromboembolism in patients with nonvalvular atrial fi brillation. Stroke. 2002;33:1005-1010 (Pubitemid 34293583)
14. Beck-da-Silva L, de BA, Fraser M, Williams K, Haddad H. Brain natriuretic peptide predicts successful cardioversion in patients with atrial fi brillation and maintenance of sinus rhythm. Can J Cardiol. 2004;20:1245-1248
15. Tveit A, Seljefl ot I, Grundvold I, Abdelnoor M, Arnesen H, Smith P. Candesartan, NT-proBNP and recurrence of atrial fi brillation after electrical cardioversion. Int J Cardiol. 2009;131(2):234-239
16. Lellouche N, Berthier R, Mekontso-Dessap A, Braconnier F, Monin JL, Duval AM, Dubois-Rande JL, Gueret P, Garot J. Usefulness of plasma B-type natriuretic peptide in predicting recurrence of atrial fi brillation one year after external cardioversion. Am J Cardiol. 2005;95:1380-1382
17. Lombardi F, Tundo F, Belletti S, Mantero A, Melzi GV. C-reactive protein but not atrial dysfunction predicts recurrences of atrial fi brillation after cardioversion in patients with preserved left ventricular function. J Cardiovasc Med (Hagerstown). 2008;9:581-588
18. Mabuchi N, Tsutamoto T, Maeda K, Kinoshita M. Plasma cardiac natriuretic peptides as biochemical markers of recurrence of atrial fi brillation in patients with mild congestive heart failure. Jpn Circ J. 2000;64:765-771
19. Costello-Boerrigter LC, Boerrigter G, Redfi eld MM, Rodeheffer RJ, Urban LH, Mahoney DW, Jacobsen SJ, Heublein DM, Burnett JC Jr. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 2006;47:345-353
20. Galasko GI, Lahiri A, Barnes SC, Collinson P, Senior R. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? Eur Heart J. 2005;26:2269-2276
21. Wallen T, Landahl S, Hedner T, Nakao K, Saito Y. Brain natriuretic peptide predicts mortality in the elderly. Heart. 1997;77:264-267 (Pubitemid 27122781)
22. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350:655-663
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
24. Vinch CS, Rashkin J, Logsetty G, Tighe DA, Hill JC, Meyer TE, Rosenthal LS, Aurigemma GP. Brain natriuretic peptide levels fall rapidly after cardioversion of atrial fi brillation to sinus rhythm. Cardiology. 2004;102:188-193
25. Tsuchida K, Tanabe K. Infl uence of paroxysmal atrial fi brillation attack on brain natriuretic peptide secretion. J Cardiol. 2004;44:1-11.
26. Wozakowska-Kaplon B, Opolski G. Effects of sinus rhythm restoration in patients with persistent atrial fi brillation: a clinical, echocardiographic and hormonal study. Int J Cardiol. 2004;96:171-176
27. Loke I, Squire IB, Davies JE, Ng LL. Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate. Eur J Heart Fail. 2003;5:599-606.
28. Krauser DG, Lloyd-Jones DM, Chae CU, Cameron R, Anwaruddin S, Baggish AL, Chen A, Tung R, Januzzi JL Jr. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) sub study. Am Heart J. 2005;149:744-750
29. Bayes-Genis A, DeFilippi C, Januzzi JL Jr. Understanding amino-terminal pro-B-type natriuretic peptide in obesity. Am J Cardiol. 2008;101(3A):89-94.
30. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, Vasan RS. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109:594-600.
31. Tagore R, Ling LH, Yang H, Daw HY, Chan YH, Sethi SK. Natriuretic Peptides in Chronic Kidney Disease. Clin J Am Soc Nephrol. 2008;3(6):1644-1651
32. Davis ME, Richards AM, Nicholls MG, Yandle TG, Frampton CM, Troughton RW. Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation. 2006;113:977-985